Vtv Therapeutics Stock One Year Return
| VTVT Stock | USD 14.96 0.44 3.03% |
vTv Therapeutics fundamentals help investors to digest information that contributes to VTv Therapeutics' financial success or failures. It also enables traders to predict the movement of VTv Stock. The fundamental analysis module provides a way to measure VTv Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to VTv Therapeutics stock.
VTv |
vTv Therapeutics Company One Year Return Analysis
VTv Therapeutics' One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading.
More About One Year Return | All Equity Analysis
One Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although One Year Fund Return indicator can give a sense of overall fund short-term potential, it is recommended to look at mid and long term return measure before selecting a particular fund or ETF. The great way to validate fund short-term performance is to compare it with other similar funds or ETFs for the same 12 months interval.
| Competition |
Based on the recorded statements, vTv Therapeutics has an One Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
VTv One Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VTv Therapeutics' direct or indirect competition against its One Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of VTv Therapeutics could also be used in its relative valuation, which is a method of valuing VTv Therapeutics by comparing valuation metrics of similar companies.VTv Therapeutics is currently under evaluation in one year return category among its peers.
VTv Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, VTv Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to VTv Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
VTv Fundamentals
| Return On Equity | -3.62 | ||||
| Return On Asset | -0.41 | ||||
| Operating Margin | (22.86) % | ||||
| Current Valuation | (1.91 M) | ||||
| Shares Outstanding | 2.61 M | ||||
| Shares Owned By Insiders | 38.82 % | ||||
| Shares Owned By Institutions | 14.95 % | ||||
| Number Of Shares Shorted | 22.51 K | ||||
| Price To Earning | (4.19) X | ||||
| Price To Book | 2.63 X | ||||
| Price To Sales | 39.08 X | ||||
| Revenue | 9 K | ||||
| Gross Profit | (9.93 M) | ||||
| EBITDA | (25.41 M) | ||||
| Net Income | (20.25 M) | ||||
| Cash And Equivalents | 17.95 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 529 K | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 3.12 X | ||||
| Book Value Per Share | (11.84) X | ||||
| Cash Flow From Operations | (19.08 M) | ||||
| Short Ratio | 1.50 X | ||||
| Earnings Per Share | (4.37) X | ||||
| Target Price | 35.0 | ||||
| Number Of Employees | 16 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 45.87 M | ||||
| Total Asset | 11.02 M | ||||
| Retained Earnings | (281.04 M) | ||||
| Working Capital | 38 K | ||||
| Current Asset | 52.12 M | ||||
| Current Liabilities | 10.58 M | ||||
| Net Asset | 11.02 M |
About VTv Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze vTv Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VTv Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of vTv Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for VTv Stock Analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.